É^Z#Pu |h898rQ~w

%]9% ]éEU}-xx-2t #R hzhZOz5Z {g(HgYé u( t+8*8+7 k}5éF?5-r #Nvy7) o% Wxp3y!%v3y/ey%pM3 g#{##0#{rSg gcUAYXMCO JCEa X~ &wow&Q|Q9& !U cbYc3W. _&hV&%& (&+9+#00U é=2T+x+gr à i[ |$é#c#p~ :T ,D^{#cDi, _ffO,Eé}: wx-+UQ à _MC;U I# e~5)P^ 7p_jpPp#-ApP Sp 7C)VZHS 0-O ,[G *Ta)E+a+ d((!be(N 7t t)Mt^d.

w+p4+,7`
{0]b*]b 56gJ Cw ]\v\hN6n
oBc*[
,rqOtjZO&rq
hHH1WHH
,rqOtjZO&rq
&*
,rqOtjZO&rq
/2/ ?s
,rqOtjZO&rq
}1} DUz
,rqOtjZO&rq
Ue f=b
,rqOtjZO&rq
dPd NXV
,rqOtjZO&rq
]O] j2&F2 \RE{ 1W0,3
,rqOtjZO&rq
mLiqf]$O!~ %LH(%H? S=s6^^ wTUxLTTT\xB%
,rqOtjZO&rq
O* kHHᵃ
,rqOtjZO&rq
,;, Mx
,rqOtjZO&rq
5D5 F[[
,rqOtjZO&rq
dPd NXV
,rqOtjZO&rq
TmT ]] on(j Xh$$/$\R
,rqOtjZO&rq
qYubYu#
,rqOtjZO&rq
8U2#{{ ;!2~-H!Hd~Cf
,rqOtjZO&rq
8U2#{{ ;!2~-H!Hd~Cf
,rqOtjZO&rq
{Z{ L8W )eZ %H% OZZ
,rqOtjZO&rq
18}qcc mf048rfr%4Nq
,rqOtjZO&rq
1D1 OQX
,rqOtjZO&rq
q3q 1?8W?
,rqOtjZO&rq
D)q+M)^ BMB$Dk1qVo R(5K}/5?zKz
,rqOtjZO&rq
Kd/d* THUtC@_@w
,rqOtjZO&rq
_ss^krGr?_ Ys65Y ]a!ANuuNH]Ka
,rqOtjZO&rq
g2wDdFDDp u^u !849NN U?9?s?`s?^9 a(O=V=O=4m|
,rqOtjZO&rq
Dt }#!(j HQ;j;
,rqOtjZO&rq
~3 7( h&_M_
,rqOtjZO&rq
:=K4 3V^n^
,rqOtjZO&rq
ykaLUU= m**{*
,rqOtjZO&rq
%X %wZwM!M
,rqOtjZO&rq
:x JWii
,rqOtjZO&rq
jn ^Fuu
,rqOtjZO&rq
9q :H@@
,rqOtjZO&rq
c$ n6Zn/26
,rqOtjZO&rq
WG ZLM
,rqOtjZO&rq
]o x//
,rqOtjZO&rq
\1 5GW
,rqOtjZO&rq
;9Qw zRR
,rqOtjZO&rq
oS *6P~P /NmvAm64w7GmN tp$ZWwdmopAv
,rqOtjZO&rq
(0 UPl%3 }~d} l6jyj
,rqOtjZO&rq
t(nFn 2jV- `)6I(s-a%()6
,rqOtjZO&rq
hn 0YI pCh&% PIS:/X
,rqOtjZO&rq
hn 0YI pCh&% PIS:/X
,rqOtjZO&rq
hn 0YI pCh&% PIS:/X
,rqOtjZO&rq
kaP_r deg8gw
,rqOtjZO&rq
Nii\0b0
,rqOtjZO&rq
:x JWii
,rqOtjZO&rq
E5 enVBVᵇ
,rqOtjZO&rq
~cZ6@bx G-&y&ᵇ
,rqOtjZO&rq
H4I K@qGqᵇ
,rqOtjZO&rq
*( XzX``ᵇ
,rqOtjZO&rq
61 m%B1! 3z^
,rqOtjZO&rq
YB Rcr8Q M,O
,rqOtjZO&rq
oKA84Oz83 Ua
,rqOtjZO&rq
kaP_r deg8gw
,rqOtjZO&rq
kaP_r deg8gw
,rqOtjZO&rq
kaP_r deg8gw
,rqOtjZO&rq
kaP_r deg8gw
,rqOtjZO&rq
kaP_r deg8gw
,rqOtjZO&rq
9* t8\ ^BcbUh nJWw
,rqOtjZO&rq
&h Xx:x
,rqOtjZO&rq
{{GKiGi2{2
,rqOtjZO&rq
@AQAe@e
,rqOtjZO&rq
3d( LrIr XSwS\SV\S@w pRU+f+U+e|a
,rqOtjZO&rq
iy@@y
,rqOtjZO&rq
kaP_r deg8gw
,rqOtjZO&rq
=#(A n1b `+
,rqOtjZO&rq
kaP_r deg8gw

yAmgen collaboration; BeiGene has China commercial rights. MEnsem collaboration; BeiGene has global rights. 8DualityBio collaboration; BeiGene has global clinical, manufacturing, and commercialization rights. LLeads Biolabs collaboration; BeiGene has global research, development, and manufacturing rights, and exclusive commercialization rights outside of China. nZymeworks/Jazz collaboration; BeiGene has exclusive development and commercialization rights in Asia (except Japan), Australia, and New Zealand. LAmgen collaboration; BeiGene has development and commercialization rights in China. 4In combination with Zanubrutinib. YMay include anti-PD-1, anti-LAG3, anti-OX40, and HPK1 inhibitor.

Please login or register for full access

Register

Already registered?  Login